Clinical Benefits of High Sensitivity Troponin

Guadalupe Regional Hospital Seguin, Texas March 2, 2022



Thomas K. Bane, PhD, PPM Director, Medical & Scientific Affairs




Areas of Focus

- > Physician Concerns:
 - Why should I do it?
 - ACC, AHA recommendation
 - AccuTnI+3 Sunset
 - How will it change what I do now?
- > Normalize Terminology
- > Accent Analytical Improvement and advantage to practice
 - Reported number acuity better assessment of micronecrosis
 - Robust number on ~everyone
 - Info earlier in potential events
 - Decision making accelerated
 - Delta provides clinical sensitivity
 - Improved clinical acuity in range >Cutoff to Critical value



Normalizing Terminology






•

Troponin Testing for Clinicians

- > Expectations:
 - 20% increase in reported results
 - 4-5% of this group will be elevated
 - Mainly women and early presenters
 - Depending upon size of delta, many of these will be referred to cardiology in next 24-48 hrs
 - Most patients ruled out quickly
- > Emphasis:

>LOD – Critical Zone (Injury/MI)

- Delta provides clinical sensitivity
 - Absolute number, not percentage change
- Resource allocation
- HEART Score Usage
- > References in the Gray Zone
 - Boeddinghaus Clin Chem 2019 Jul;65(7):893-904
 - "Yellow Zone", 0-1 hr ADP
 - Nestelberger Clin Chem 2019 Nov;65(11):1437-1447
 - "Yellow Zone", 0-2 hr ADP
 - Baugh Transition, Crit Pthwys Cardio 2020 Mar;18(1):1-4
 - "Grey Zone" & HEART Score (TnT)



Range of Possible Troponin Levels



Troponin Testing for Clinicians continued

- > Greenslade J Clin Med 2020 Jun 16;9(6):1883-1895
 - 6 mos AccuTnI+3 6 mos hsTnI
 - 63K/61K patients
 - Outcomes
 - Primary
 - i. Decreased Hospital LOS
 - ii. Increase in elevated cTn values
 - iii. No concomitant increase in cardiac admissions, invasive coronary procedures or diagnosis of AMI
 - Secondary
 - i. Decreased ED LOS, 90-day CV mortality,
 - ii. Following adoption:
 - Decrease single cTn order.
 - Increased dual cTn orders More Deltas
 - iii. Increased detection of myocardial injury
 - Male 5%, Female 12%
 - Diagnostic rates remain unchanged
 - iv. Significant economic savings.




Guideline Recommendations

- > Thygesen etal 2019 Eur Heart Jrnl 40, 237-269
 - Fourth universal definition of myocardial infarction
 - "cTnl and cTnT are the preferred buimarkers for the evaluation of myocardial injury, and high-sensitivity (hs)cTn assays are recommended for routine clinical use."
 - "Very low levels of hs-Tn on presentation or the lack of any change and persistently normal hs-cTn values over a 1-2 hour period after presentation have been advocated to exclude acute myocardial injury, and MI as well."




- > AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Clinical Practice Guidelines
 - Gulati etal 2021 Circulation; 144:00-00 (November 2021)
 - Guideline for the Evaluation & Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
 - i. High-Sensitivity Troponins Preferred






What Stays the Same





Different: Improved Precision at 99th Percentile







Troponin Levels

What is Different?

- > Enhanced Analytical Sensitivity
- > **Units** ng/ml to pg/ml.
 - 0.03 ng/ml is now a 30 pg/ml
- > Delta Instead of Cutoff
- > Male/Female-Specific 99th Percentile URL
- > Troponin Number on Almost All Patients
- Shorter Draw Protocols
 - 0-1, 0-2, 0-1-3

Parameter	AccuTnl +3*	Access hsTnl UniCel Dxl
LoD (pg/mL)	10	2.3
10% CV (pg/mL)	40	5.6
20% CV (pg/mL)	30	2.3


pg/ml

pg/ml



What is different?

Reference Interval – population distribution






.

Additional Values at Low End are Relevant

Approx 20% of AMI patients had initial Troponin BELOW 99th Percentile



Hs-cTnI concentration at presentation vs. final diagnoses




Boeddinghaus, Clin Chem 2019 65:7

© 2020 Beckman Coulter, Inc. All rights reserved.

Publi

The Spectrum of Troponin Values



Circulation. 2018;138:e618–e651


19

© 2020 Beckman Coulter, Inc. All rights reserved.




Publi

22 © 2020 Beckman Coulter, Inc. All rights reserved.



•

What is Different: Deltas




Increasing Troponin Concentrations

	LoD (10)	20% CV	10% CV (40)	Contemporary Troponin Assays*
LoD (2.0)	10% CV (4.1)	4% CV		High Sensitivity Troponin Assays*



Absolute vs. Relative Delta

Delta troponin for the early diagnosis of AMI in emergency patients with chest pain. Cullen 2013. Int J Cardiol 168(3):2602-8.





23 © 2020 Beckman Coulter, Inc. All rights reserved.

•

Case Study

> Contemporary Practice:


- 42 year old female presents to ED with nausea, vomiting, trouble breathing
- Normal sinus rhythm, left ventricle hypertrophy. 2nd ECG noted ST elevation
- Final Diagnosis:
 - Acute MI STEMI
- Patient received IV tissue plasminogen activator

	Current assay (ng/mL)	Current assay (pg/mL)	hsTnl (pg/mL)
Baseline	< 0.03	<30	14
3 hr.	< 0.03	<30	36
6 hr.	0.63	630	562
12 hr.	26.43	26430	18762


Emergent Practice:

- Baseline hsTnI level is above 99th percentile for females >12pg/mL
- 3hr troponin level also abnormal, including significant change as compared to baseline.
- This pattern is seen with early presenters.






Who Benefits?





Cardiovascular Disease Mortality Trends

Women's rates are not declining in line with men's








27 © 2020 Beckman Coulter, Inc. All rights reserved.

Publi


٠

Reduced Patient Waiting Time in the A&E

52% fewer patients presenting to A&E with chest pain are waiting longer than 4 hours following implementation of Access hsTnI in Q1 2018/19



An average of 52% fewer patients with CP wait >4hrs in A&E since the introduction of Access hsTnI



© 2020 Beckman Coulter, Inc. All rights reserved.

Reference interval – 99th percentile URL: Dxl

UniCel DxI (plasma) results:

99 th Percentile URL	Access hsTnl	AccuTnl+3
Overall N = 1088	17.9 pg/mL	<30 pg/mL (<0.03 ng/mL)
Female N = 593	14.9 pg/mL	N/A
Male N = 495	19.8 pg/mL	N/A



•


Clinical trial – Results

- Identifies most true AMI patients in as little as one hour post presentation
- > 99% NPV in as little as one hour after ED admission
- > Specificity
 - Increases with change from 30ng/L (AccuTnI+3) to 18ng/L (hsTnI).
 - For sex-specific cutoffs
 - Sensitivity & Specificity improve for females

99 th %URL cutoff, ng/L	Hours After Admission to ED	Sensitivity, %	Specificity, %	PPV, %	NPV, %
	Baseline	88	89	58	98
17.9	≥1-3 hour	94	90	54	99
Overall	≥3-6 hour	94	90	55	99
	≥6-9hour	99	85	51	100
	Baseline	83	91	53	98
14.9	≥1-3 hour	93	92	47	99
Females	≥3-6 hour	96	92	51	100
	≥6-9hour	100	88	45	100
	Baseline	89	87	61	97
19.8 Males	≥1-3 hour	96	88	57	99
	≥3-6 hour	94	88	58	99
	≥6-9hour	98	81	53	100



Medical Decision Point Correlation – 20-200 pg/ml






4 © 2020 Beckman Coulter, Inc. All rights reserved.


Publi

Cardiac Troponin Medical Cutoffs/Medical Decision Points






ED Chest Pain Protocol



This protocol does NOT replace clinical judgement, but should be referred to as a best standard practice guideline.

hsTnl transition at St. Lukes Bethlehem, PA



Publi

•

SharpHealth Care Decision Making

High Sensitivity Troponin I – Result Algorithm

Clinical judgement supersedes the algorithm especially in high risk patients or patients with unusual symptoms or an unstable/concerning ECG.

Draw Times	Move to Rule-Out AMI	Move to Rule-In AMI
0 hour	≤5.0 pg/mL	>99.0 pg/mL Males >75.0 pg/mL Females
 <u>0 - 2 hours</u> >5.0 pg/mL and Below the Cutoff Male - 19.8 pg/mL Female - 14.9 pg/mL Significant HEART score/clinical presentation 	∆ <5.0 pg/mL*	∆ >15.0 pg/mL
 <u>0 - 2 hours</u> Above the Cutoff Male - 19.8 pg/mL Female - 14.9 pg/mL 	Δ <5.0 pg/mL*	Δ >15.0 pg/mL


* Δ between 5-15 pg/mL need to be interpreted with clinical context.

Possible Non-Ischemic causes of elevated troponins: Tachyarrhythmias, congestive heart failure, critically ill patients (sepsis, respiratory failure, inflammatory diseases, burns), pulmonary embolism or severe pulmonary hypertension, severe hypertension or hypotension, apical ballooning cardiomyopathy (Takotsubo Syndrome), stroke or subarachnoid hemorrhage, renal failure, myocarditis, myopericarditis, cardioversion or ablations, aortic stenosis, chest trauma, hypertrophic cardiomyopathy, coronary spasm, hypothyroidism, infiltrative cardiomyopathy, extreme exertion, drug toxicity (some chemotherapies).

Reference: Clinical Use of High-Sensitivity Cardiac Troponin in Patients with Suspected Myocardial Infarction R Twerenbold et al. J Am Coll Cardiol 70 (8), 996-1012. 2017.



hsTn Implementation in the Clinic



Physician buy-in is critical Audit, assess, communicate, repeat



THANK YOU



Move nealthcare forward.

© 2017 Beckman Coulter. All rights reserved.